GlycoErase™ ALG3 Knockout Human Skin Cancer Cell A2058 (CAT#: GLJF-0525-JF899)

Description	The ALG3 knockout in A2058 cells is essential for unraveling the complexities of early N-glycosylation events and the resultant aberrant glycan structures, thus allowing researchers to delineate the influence of these glycosylation anomalies on melanoma cell behavior, chemoresistance profiles, and the discovery of glycosylatioN-related biomarkers and therapeutic strategies.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial cells, adherent
Passage Ratio	1:2~1:3
Cell Line	A2058
Primary Disease	Melanoma
Lineage	Skin

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	EMEM & FBS & Glutamine
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	ALG3
Full Name	ALG3 alpha-1,3- mannosyltransferase
Alternative Name	NOT56L, D16Ertd36e, CDGS4, Not56
Location	3q27.1
Gene ID	10195
Summary	Key player in N-glycosylation, adding alpha 1,3 mannose (dol-P-Man to Man5GlcNAc2-PP-Dol); disruptions linked to CDG-Id (congenital disorder of glycosylation type Id), causing abnormal N-glycosylation and potential neurological issues.